It was pointed out that amid intensifying competition in countries around the world over the supply and demand of COVID-19 vaccine, there is a low possibility that a domestic vaccine will be marketed within this year, increasing public anxiety.

Compared to the fact that about three domestic-made COVID-19 treatments are expected to be marketed within the year, domestic vaccines are planned to be used in a phase 3 clinical trial at the end of the year, so they can only be approved for use next year. This was revealed through the 'COVID-19 Treatment and Vaccine Domestic Clinical Support Status' data submitted by the KHIDI.